IP Verse

B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of Cancer - EP1810026

The patent EP1810026 was granted to Mayo Foundation FOR Medical Education And Research on Apr 18, 2018. The application was originally filed on Oct 6, 2005 under application number EP05808659A. The patent is currently recorded with a legal status of "Revoked".

EP1810026

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Application Number
EP05808659A
Filing Date
Oct 6, 2005
Status
Revoked
Apr 12, 2024
Grant Date
Apr 18, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JANSSEN BIOTECHJan 18, 2019CARPMAELS & RANSFORDADMISSIBLE
MERCK SHARP & DOHMEJan 16, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20000649108-
DESCRIPTIONUS20020728202-
DESCRIPTIONUS20030719477-
DESCRIPTIONWO2002US32364-
DESCRIPTIONUS2003039653
DESCRIPTIONUS6803192
DESCRIPTIONWO2004004771
DESCRIPTIONWO2004077060
DESCRIPTIONWO2006133396
EXAMINATIONEP1537878
INTERNATIONAL-SEARCH-REPORTUS2003039653
INTERNATIONAL-SEARCH-REPORTUS2006110383
OPPOSITIONEP1537878
OPPOSITIONUS2003039653
OPPOSITIONWO2004004771
OPPOSITIONWO2004056875
OPPOSITIONWO2004073732
SEARCHUS2003039653
SEARCHUS2006110383
SEARCHWO0200730
SEARCHWO2004004771
SEARCHWO2004077060
SEARCHWO2006133396

Non-Patent Literature (NPL) Citations (49) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- ESZTER LÁZÁR-MOLNÁR ET AL, "Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20080718), vol. 105, no. 30, pages 10483 - 10488, XP055198268-
EXAMINATION- FLIES DALLAS B ET AL, "Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy", YALE JOURNAL OF BIOLOGY AND MEDICINE, NEW HAVEN, CT, US; BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20111201), vol. 84, no. 4, pages 409 - 421, XP002711444-
EXAMINATION- DONG HAIDONG ET AL, "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20020624), vol. 8, no. 8, ISSN 1078-8956, pages 793 - 800, XP002397368
EXAMINATION- Lieping Chen, "Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity", Nature Reviews Immunology, (20040501), vol. 4, no. 5, doi:10.1038/nri1349, ISSN 1474-1733, pages 336 - 347, XP055141186
EXAMINATION- Yoshiko Iwai ET AL, "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.", International Immunology, (20050201), vol. 17, no. 2, doi:10.1093/intimm/dxh194, ISSN 0953-8178, pages 133 - 144, XP055142463
EXAMINATION- J. M. TAUBE ET AL, "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy", CLINICAL CANCER RESEARCH, US, (20140408), vol. 20, no. 19, doi:10.1158/1078-0432.CCR-13-3271, ISSN 1078-0432, pages 5064 - 5074, XP055291958
EXAMINATION- EJUAN ZHANG ET AL, "The Expression of PD-1 Ligands and Their Involvement in Regulation of T Cell Functions in Acute and Chronic Woodchuck Hepatitis Virus Infection", PLOS ONE, (20111014), vol. 6, no. 10, doi:10.1371/journal.pone.0026196, page e26196, XP055198262
EXAMINATION- YAMAZAKI TOMOHIDE ET AL, "Expression of programmed death 1 ligands by murine T cells and APC", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20021115), vol. 169, no. 10, doi:10.4049/JIMMUNOL.169.10.5538, ISSN 0022-1767, pages 5538 - 5545, XP002398158
OPPOSITION- Anonymou, "Mayo Clinic Policies and Guidelines for Relationships with Industry, Publishing", Mayo Foundation, (20031009), Mayo Foundation, (20240315), XP093141656-
OPPOSITION- BROWN et al., "Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production", Journal of Immunology, (20030000), vol. 170, pages 1257 - 1266, XP002973918-
OPPOSITION- DONG et al., "B7-H1 pathway and its role in the evasion of tumor immunity", Journal of Molecular Medicine, (20030000), vol. 81, no. 5, pages 281 - 287, XP008068401-
OPPOSITION- KUDO et al., "Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells", Cancer Research, (20030000), vol. 63, pages 1676 - 1683, XP055553464-
OPPOSITION- MAZANET et al., "B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis", The Journal of Immunology, (20020000), vol. 169, pages 3581 - 3588, XP002311469-
OPPOSITION- SAUDEMONT et al., "In a model of tumor dormancy, long-tenn persistent leukemic cells have increased B7-Hl and B7.l expression and resist CTL-mediated lysis", Blood, (20040000), vol. 104, no. 7, pages 2124 - 2133, XP055553405-
OPPOSITION- STÖRKEL, S. et al., "Morphological classification of renal cancer", World J Urol, (19950000), vol. 13, no. 3, pages 153 - 158, XP055553531-
OPPOSITION- STROME et al., "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma", Cancer Research, (20030000), vol. 63, no. 19, pages 6501 - 6505, XP002487684-
OPPOSITION- TAKAHASHI et al., The Japanese Journal of Urology, (20040000), vol. 95, no. 2, page 369-
OPPOSITION- WINTTERLE et al., "Expression of the B7-Related Molecule B7-H1 by Glioma Cells: A Potential Mechanism of Immune Paralysis", Cancer Research, (20030000), vol. 63, no. 21, pages 7462 - 7467, XP055406234-
OPPOSITION- CARTER et al., "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2", European Journal of Immunology, (20020000), vol. 32, pages 634 - 643, XP002980901
OPPOSITION- DONG et al., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", Nature Medicine, (20020000), vol. 8, no. 8, pages 793 - 800, XP002397368
OPPOSITION- CURIEL et al., "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", Nature Medicine, (20030000), vol. 9, no. 5, pages 562 - 567, XP002311470
OPPOSITION- CHEN, "Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity", Nature Reviews Immunology, (20040000), vol. 4, no. 5, pages 336 - 347, XP055141186
OPPOSITION- CHEN, L. et al., "Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity", Nature Reviews Immunology, (20040500), vol. 4, no. 5, pages 336 - 347, XP055141186
OPPOSITION- THOMPSON et al., "Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target", PNAS, (20040000), vol. 101, no. 49, pages 17174 - 17179, XP002520405
OPPOSITION- THOMPSON, R. H. et al., "Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target", PNAS, (20041207), vol. 101, no. 49, pages 17174 - 17179, XP002520405
OPPOSITION- IWAI et al., "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PNAS, (20020917), vol. 99, no. 19, pages 12293 - 12297, XP002398159
OPPOSITION- IWAI, Y. et al., "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells", International Immunology, (20041220), vol. 17, no. 2, pages 133 - 144, XP055142463
OPPOSITION- CHEVILLE et al., "Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma", The American Journal of Surgical Pathology, (20030000), vol. 27, pages 612 - 624, XP055553436
OPPOSITION- BLANK et al., "PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells", Cancer Research, (20040000), vol. 64, no. 3, pages 1140 - 1145, XP009076235
OPPOSITION- ATKINS et al., "Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma", Clinical Cancer Research, (20040000), vol. 10, no. 18, pages 6342 - 6346, XP055553409
OPPOSITION- KONISHI et al., "B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression", Clinical Cancer Research, (20040000), vol. 10, no. 15, pages 5094 - 5100, XP055292163
OPPOSITION- ZHA et al., "Negative regulation of T-Cell function by PD-1", Critical Reviews in Immunology, (20040000), vol. 24, no. 4, pages 229 - 237, XP009158087
OPPOSITION- YAMAZAKI et al., "Expression of programmed death 1 ligands by murine T cells and APC", The Journal of Immunology, (20020000), vol. 169, no. 10, pages 5538 - 5545, XP002398158
OPPOSITION- YAMAZAKI, T. et al., "Expression of programmed death 1 ligands by murine T cells and APC", THE JOURNAL OF IMMUNOLOGY, (20021115), vol. 169, no. 10, pages 5538 - 5545, XP002398158
OTHER- CHEN, "Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity", Nature Reviews Immunology, (20040500), vol. 4, no. 5, pages 336 - 347, XP055141186
OTHER- IWAI et al., "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells", International Immunology, (20041220), vol. 17, no. 2, pages 133 - 144, XP055142463
OTHER- YAMAZAKI et al., "Expression of Programmed Death 1 Ligands by Murine T Cells and APC", Journal of Immunology, (20021115), vol. 169, no. 10, pages 5538 - 5545, XP002398158
SEARCH- DATABASE WPI, 0, Derwent World Patents Index, vol. 2004, no. 11, Database accession no. 2004-108719, XP002520406 & WO2004004771 A 20040115 (HONJO T) [X] 27-30,32,35,36,39 * abstract *-
SEARCH- HE LANXIANG ET AL, "BLOCKADE OF B7-H1 WITH SPD-1 IMPROVES IMMUNITY AGAINST MURINE HEPATOCARCINOMA", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, GREECE, (20050901), vol. 25, no. 5, ISSN 0250-7005, pages 3309 - 3313, XP009078741 [PX] 27,29-31,35 * the whole document * [PY] 33,34-
SEARCH- HIRANO FUMIYA ET AL, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 1089 - 1096, XP002419626 [PX] 27-30,32,35 * the whole document * [PY] 33,34-
SEARCH- MAZANET M M ET AL, "B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20021001), vol. 169, no. 7, ISSN 0022-1767, pages 3581 - 3588, XP002311469 [Y] 33,34 * the whole document *-
SEARCH- STROME SCOTT E ET AL, "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, (20031001), vol. 63, no. 19, ISSN 0008-5472, pages 6501 - 6505, XP002487684 [X] 27-30,32,35 * the whole document * [Y] 33,34-
SEARCH- THOMPSON R H ET AL, "Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, (20051005), vol. 104, no. 10, ISSN 0008-543X, pages 2084 - 2091, XP008091323 [PX] 1-3,6-12,15-20,23-26 * the whole document *
SEARCH- THOMPSON ET AL, "B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma", UROLOGY, BELLE MEAD, NJ, US, (20050927), vol. 66, no. 5, ISSN 0090-4295, pages 10 - 14, XP005091603 [PX] 27-30,32,35,42 * the whole document * [PY] 33,34
SEARCH- CURIEL T J ET AL, "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20030501), vol. 9, no. 5, ISSN 1078-8956, pages 562 - 567, XP002311470 [X] 27-30,32,35 * the whole document * [Y] 33,34
SEARCH- THOMPSON R HOUSTON ET AL, "Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 7 DEC 2004, (20041207), vol. 101, no. 49, ISSN 0027-8424, pages 17174 - 17179, XP002520405 [PX] 1-3,6-12,15-20,23-26 * the whole document * [PY] 33,34
SEARCH- IWAI YOSHIKO ET AL, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20020917), vol. 99, no. 19, ISSN 0027-8424, pages 12293 - 12297, XP002398159 [X] 27-30,32,35 * the whole document * [Y] 33,34
SEARCH- OHIGASHI YUICHIRO ET AL, "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050415), vol. 11, no. 8, ISSN 1078-0432, pages 2947 - 2953, XP002419631 [PX] 1-6,9-15,17 * the whole document *
SEARCH- ZHANG XIAOYU ET AL, "B7-H1-targeted immunotherapy for head and neck cancer", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (20041001), vol. 4, no. 10, ISSN 1471-2598, pages 1577 - 1583, XP008095722 [X] 27-30,32,35 * the whole document * [Y] 33,34

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents